September 27, 2016
Clinical findings presented at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference EAGAN, MN — September 27, 2016 — Biothera Pharmaceuticals, Inc. today announced the presentation of clinical data demonstrating the mechanism of action of Imprime PGG, the Company’s Phase 2 cancer immunotherapy drug, in healthy human volunteers. These are the first data to show that when administered intravenously to healthy human subjects, Imprime PGG drives the immunopharmacodynamic...
Read More
August 24, 2016
Biothera’s Imprime PGG and Merck’s anti-PD-1 inhibitor KEYTRUDA® (pembrolizumab) to be evaluated in combination for patients with either advanced melanoma or metastatic triple negative breast cancer (TNBC) Under previous agreement, Big Ten Cancer Research Consortium (BTCRC) plans to initiate a Phase 1b/2 Imprime PGG/KEYTRUDA trial in patients with non-small cell lung cancer (NSCLC) EAGAN, MN — August 24, 2016 — Biothera Pharmaceuticals, Inc. today announced...
Read More
August 3, 2016
EAGAN, MN — August 3, 2016 — Biothera Pharmaceuticals, Inc. today announced that Chief Executive Officer Barry Labinger will present at the Canaccord Genuity 36th Annual Growth Conference on Wednesday, August 10, 2016 at 11:30 a.m. Eastern Time in Boston, Mass. Mr. Labinger will provide an overview of Biothera Pharmaceuticals and a business update. About Biothera Pharmaceuticals, Inc.Biothera Pharmaceuticals is a privately held biotechnology company...
Read More
May 31, 2016
EAGAN, MN — May 31, 2016 — Biothera Pharmaceuticals, Inc. today announced that Chief Executive Officer Barry Labinger will present at the Sachs Associates 2nd Annual Immuno-Oncology BD&L and Investment Forum on Friday, June 3, 2016 at 2:30 p.m. Central Time in Chicago. Mr. Labinger will provide an overview of Biothera and its clinical development plans in oncology, which include the initiation of three Phase...
Read More
April 18, 2016
EAGAN, MN — April 18, 2016 — Biothera Pharmaceuticals, Inc. today announced research providing new insights into the ability of the Company’s Phase 2 cancer immunotherapy to coordinate innate and adaptive immune responses and enhance the effectiveness of combination therapies. The findings were presented today at the AACR annual meeting, which is taking place in New Orleans, LA, April 16-20, 2016. The company is presenting...
Read More
April 4, 2016
EAGAN, MN — April 4, 2016 — Biothera Pharmaceuticals, Inc. today announced that Barry Labinger, Chief Executive Officer, will present at the 3rd Annual Jefferies Immuno-Oncology Summit on Friday, April 8, 2016 at 1:15p.m. Eastern Time in Boston, Mass. Mr. Labinger will provide an overview of Biothera and its clinical development plans in oncology. About Biothera Pharmaceuticals, Inc.Biothera Pharmaceuticals is a privately held biotechnology company...
Read More
March 16, 2016
EAGAN, MN — March 16, 2016 — Biothera Pharmaceuticals Inc. announced today that it will present five scientific posters at the American Association for Cancer Research (AACR) Annual Meeting April 16-20 in New Orleans. Three of the posters were selected for the high profile, late-breaking research sessions—sessions devoted to the newest, most exciting research of the year. Details of the presentations are as follows: Poster Presentations:...
Read More
March 10, 2016
EAGAN, MN — March 10, 2016 — Biothera Pharmaceuticals Inc. today will present data on its Phase 2 cancer immunotherapy Imprime PGG, the Company’s first-in-class, systemically administered beta glucan PAMP (Pathogen Associated Molecular Patterning molecule) at Cambridge Healthtech Institute’s Molecular Medicine Tri-Conference 2016, taking place at the Moscone Convention Center, San Francisco. Jeremy Graff, Ph.D., Chief Scientific Officer and Senior Vice President, Research at Biothera...
Read More
February 25, 2016
Results published in Investigational New Drugs: The Journal of New Anticancer Agents Imprime PGG (Beta 1,3/1,6 glucan) also has established proof of concept as an immuno-oncology therapy in subsequent single arm and randomized Phase 2 studies With significant milestones anticipated throughout 2016, Biothera is advancing Imprime PGG towards registration trials by 2018 EAGAN, MN — February 25, 2016 — Biothera Pharmaceuticals Inc. today announced the peer-reviewed...
Read More
February 2, 2016
EAGAN, MN — February 2, 2016 — Biothera Pharmaceuticals Inc. announced today that Barry Labinger, Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 10:00a.m. Eastern Time in New York, NY. Mr. Labinger will provide an overview of Biothera and business update. Biothera Pharmaceuticals Inc. was selected as the winner of the “Most Buzzworthy...
Read More
